Burkhardt Valentin, El-Shabrawi Katharina, Riemann Sarah, Voss Pit, Becker Christoph
Department of Otorhinolaryngology-Head and Neck Surgery, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Department of Oral and Craniomaxillofacial Surgery, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Front Oral Health. 2024 Nov 15;5:1493319. doi: 10.3389/froh.2024.1493319. eCollection 2024.
The purpose of the study was to assess the impact of a pretherapeutic Multidisciplinary Tumor Board (MTB) presentation on the prognosis and treatment outcomes in patients with primary oral cavity carcinoma.
This single-center study included 630 patients diagnosed with oral cavity carcinoma treated between 2010 and 2020. The study cohort was divided in a group with and without pretherapeutic MTB presentation. Data on patient demographics, tumor characteristics, treatment and the time to treatment initiation (TTI) were collected retrospectively.
Primary findings revealed no significant difference in 3-year survival rate (3-YSR) and 3-year disease-free survival rate (3-YDFSR) for the non-MTB and MTB group. The 3-YSR was 73.1% in the non-MTB group and 67.1% in the MTB group ( 0.112). The 3-YDFSR was 73.8% in the non-MTB group and 76.5% in the MTB group ( = 0.447). Estimated mean 5-year survival (5-YS) and 5-year disease-free survival in (5-YDFS) did not differ significantly between both groups, across the UICC stages I-IV, as well as for the entire cohort. The TTI was significantly longer in the MTB group (33.5 days, CI: 31.3;35.7) compared to the non-MTB group (20.1 days, CI: 17.9;22.4, < 0.001). The MTB group adhered more frequently to the national guidelines (68% vs. 79.6%, < 0.01).
The results demonstrate both positive and negative side effects of the MTB presentation in patients with oral cavity cancer. Further multicenter studies will be required to assess the impact of TTI and adherence to guidelines on the survival of oral cavity cancer patients.
本研究旨在评估治疗前多学科肿瘤委员会（MTB）报告对原发性口腔癌患者预后和治疗结果的影响。
这项单中心研究纳入了2010年至2020年间诊断为口腔癌并接受治疗的630例患者。研究队列分为有和没有治疗前MTB报告的两组。回顾性收集患者人口统计学、肿瘤特征、治疗及治疗开始时间（TTI）的数据。
主要研究结果显示，非MTB组和MTB组的3年生存率（3-YSR）和3年无病生存率（3-YDFSR）无显著差异。非MTB组的3-YSR为73.1%，MTB组为67.1%（P=0.112）。非MTB组的3-YDFSR为73.8%，MTB组为76.5%（P=0.447）。在国际抗癌联盟（UICC）I-IV期以及整个队列中，两组间的估计平均5年生存率（5-YS）和5年无病生存率（5-YDFS）无显著差异。MTB组的TTI显著长于非MTB组（33.5天，95%置信区间：31.3；35.7），非MTB组为20.1天（95%置信区间：17.9；22.4，P<0.001）。MTB组更频繁地遵循国家指南（68%对79.6%，P<0.01）。
结果表明MTB报告对口腔癌患者有积极和消极的副作用。需要进一步的多中心研究来评估TTI和遵循指南对口腔癌患者生存的影响。
